去纤维钠是哪个公司产的？

Which company is it produced by? Defibrotide sodium (defiteli) is the first drug in the United States to treat severe hepatic veno-occlusive disease. Its manufacturer is Gentium Pharmaceuticals, which was later acquired by American Jazz Pharmaceuticals and was launched in the United States in 2016. Defibrinated sodium has anti-thrombotic, fibrinolytic, anti-ischemic and anti-infectious effects in vivo and in vitro. Not only for adults, it also plays an important role in the treatment of pediatric patients.

Jazz Pharmaceuticals Public Limited Company (Jazz Pharmaceuticals) is a biopharmaceutical company. The company develops and commercializes products that address unmet medical needs. The company has a diverse portfolio of products and product candidates targeting the sleep and hematology/oncology areas.

Defibrotide sodium (Defibrotide) is an injectable medication with the recommended dose for adult and pediatric patients being 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. Concomitant use of defibrinated sodium and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before treatment, and consider delaying initiation of defibrinated sodium administration until the effects of the anticoagulants have lessened.

It has also been awarded the title of orphan drug by the US FDA. Currently, the drug has not been marketed in my country. Sodium defibrotide (Defibrinoside), a subsidiary of Jazz Pharmaceuticals, has brought a new treatment option to patients with hepatic veno-occlusive disease. If patients need to purchase this drug, they can consult a regular overseas medical consulting service company - Medical Partner Travel for specific information.

Recommended related hot articles: /newsDetail/71699.html